Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Definitive Healthcare (DH) announced the granting of an inducement award to its new Chief Commercial Officer, Tina Hannagan, consisting of 830,565 time-based restricted stock units (RSUs). The award, granted on June 1, 2025, was approved by the company's Human Capital Management and Compensation Committee as part of Hannagan's employment agreement. The RSUs will vest over a four-year period, with 25% vesting on June 1, 2026, followed by quarterly installments of 6.25% over the subsequent three years. The grant was made under Definitive Healthcare's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• Appointment of new Chief Commercial Officer strengthens executive leadership team
• Structured vesting schedule over 4 years helps retain key talent

Negative

• Potential dilution to existing shareholders from the 830,565 RSU grant

News Market Reaction – DH

+6.73%

1 alert

+6.73% News Effect

On the day this news was published, DH gained 6.73%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

FRAMINGHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that in connection with the hiring of a senior leader, that the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare’s Board of Directors granted an inducement award. The Committee granted Tina Hannagan, Definitive Healthcare’s Chief Commercial Officer, an inducement award consisting of 830,565 time-based restricted stock units (“RSUs”) effective June 1, 2025. This award was individually negotiated and was granted as an inducement material to Ms. Hannagan’s commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).

The award is subject to the terms and conditions of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and the terms and conditions of an applicable award agreement covering the grant. Ms. Hannagan’s RSUs will vest as follows, subject to Ms. Hannagan’s continued employment through each such date: (i) 25% will vest on June 1, 2026; (ii) the remainder will vest in quarterly installments equal to 6.25% of the total RSUs over the subsequent 3 years, until fully vested.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS products and solutions create new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251

Media Contact:
Bethany Swackhamer
bswackhamer@definitivehc.com

FAQ

How many RSUs were granted to Definitive Healthcare's new Chief Commercial Officer?

Tina Hannagan was granted 830,565 restricted stock units (RSUs) as an inducement award.

What is the vesting schedule for DH's Chief Commercial Officer's RSU grant?

The RSUs vest 25% on June 1, 2026, with the remainder vesting in quarterly installments of 6.25% over the following 3 years.

Who is the new Chief Commercial Officer at Definitive Healthcare (DH)?

Tina Hannagan was appointed as the new Chief Commercial Officer at Definitive Healthcare.

When was the inducement grant approved for Definitive Healthcare's CCO?

The inducement grant was effective June 1, 2025.

Under which plan were the RSUs granted to DH's new Chief Commercial Officer?

The RSUs were granted under Definitive Healthcare's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).